Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Regeneron Pharmaceuticals : Sanofi beats profit forecasts, upbeat on prospects for eczema drug

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/28/2017 | 10:30am CET
A logo is seen in front of the entrance at the headquarters of French drugmaker Sanofi in Paris

French drugmaker Sanofi's (>> Sanofi) profit beat forecasts in the first quarter and confirmed its earnings outlook for the year, lifting its shares on Friday.

French drugmaker Sanofi's (>> Sanofi) profit beat forecasts in the first quarter and confirmed its earnings outlook for the year, lifting its shares on Friday.

The results were buoyed by Sanofi's speciality care division Genzyme, as well as vaccines and consumer products it has acquired from Germany's Boehringer Ingelheim.

Earlier this year, Sanofi had warned investors it expected 2017 earnings per share to be stable or slightly lower after its fourth quarter results were affected by an increase in taxes and one-off charges.

The company had also said in 2015 it was not targeting any 'meaningful' profit growth for two years, citing difficulties in its embattled diabetes division.

"Although it has now some margin to deliver actual numbers above guidance, Sanofi also has reasons to wait a bit more before raising it. Diabetes is still a very uncertain market segment to work in," Bryan Garnier analysts said in a note.

However, Sanofi, whose shares were up more than 2 percent at 0805 GMT, said it was confident Dupixent, a drug for moderate-to-severe atopic dermatitis that was approved in the United States at the end of last month, would sell well.

Analysts forecast annual Dupixent sales of more than $4 billion (£3.10 billion) by 2022, according to Thomson Reuters data. Developed with Regeneron (>> Regeneron Pharmaceuticals Inc), the drug is seen as the most important growth driver for the two companies, who have said Dupixent will have a list price of $37,000 a year.

Sanofi Chief Executive Olivier Brandicourt told journalists that he was "very encouraged with the early coverage" of Dupixent, adding that "the launch is delivering so far exactly on our expectations".

While the price of Dupixent before discounts and rebates to insurers is far more expensive than topical medicines and steroids used to treat eczema, it is less expensive than other injectable antibody drugs for serious skin conditions, such as psoriasis, that list for about $50,000 a year.

CONSUMER HEALTHCARE SHINES

Sanofi said on Friday first-quarter business net income rose 1 percent at constant exchange rates to 1.8 billion euros (£1.51 billion). Total sales rose 8.6 percent to 8.65 billion.

Analysts polled by Reuters in partnership with Inquiry Financial had on average been expecting business net profit of 1.6 billion euros and net sales of 8.38 billion.

Genzyme's sales were up 15.5 percent while revenue at the vaccines divisions rose 22.2 percent. Consumer healthcare products sales were up 42.7 percent.

Hurt by continued U.S. pricing pressure, diabetes and cardiovascular sales however suffered another downturn with revenue falling 7.7 percent.

(Additional reporting by Matthieu Protard; Editing by Leigh Thomas and Alexander Smith)

By Matthias Blamont

Stocks treated in this article : Sanofi, Regeneron Pharmaceuticals Inc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
11/21 REGENERON PHARMACEUTICALS : Patent Issued for CHO Integration Sites and Uses (US..
11/21 REGENERON PHARMACEUTICALS : Announces Upcoming Investor Conference Presentation
11/17 REGENERON PHARMACEUTICALS : Announces Upcoming Investor Conference Presentation
11/15 REGENERON PHARMACEUTICALS : Announces Upcoming Investor Conference Presentation
11/13 Poor earnings updates keep European shares at seven-week low
11/13 NASDAQ 100 MOVERS : Disca, has
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/13 REGENERON PHARMACEUTICALS : and Sanofi to Present New Analyses from the Praluent..
11/09 REGENERON PHARMACEUTICALS : Dupilumab Significantly Reduced Steroid Use, Asthma ..
11/09 REGENERON PHARMACEUTICALS : to Share Clinical Progress of REGN1979 and Cemiplima..
More news
News from SeekingAlpha
11/20 Roche Rocks On With More Good News
11/16 YOUR DAILY PHARMA SCOOP : A Look At Sanofi, Ultragenyx Gets FDA Nod, Capricor Tu..
11/15 5 Reasons To Buy The Dip - Cramer's Mad Money (11/14/17)
11/14 YOUR DAILY PHARMA SCOOP : Heron Undervalued, Theravance Submits NDA, Nektar Cont..
11/13 YOUR DAILY PHARMA SCOOP : Regeneron's Appeal, Good News For Amgen, Bristol-Myers..
Financials ($)
Sales 2017 5 765 M
EBIT 2017 2 436 M
Net income 2017 1 451 M
Finance 2017 2 310 M
Yield 2017 -
P/E ratio 2017 31,02
P/E ratio 2018 28,66
EV / Sales 2017 6,82x
EV / Sales 2018 6,03x
Capitalization 41 637 M
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 474 $
Spread / Average Target 22%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer President, Chief Executive Officer & Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Director & Chief Scientific Officer
Charles A. Baker Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS5.57%41 637
GILEAD SCIENCES1.69%95 098
VERTEX PHARMACEUTICALS99.59%37 187
GENMAB4.94%11 692
EXELIXIS, INC.74.72%7 731
BLUEBIRD BIO INC171.07%7 663